Payment overview · 2025
General Payments
$281.49
16 reported records · 6 companies
Healthcare provider profile · identity verified
Darryl John Wilkens, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JELLICO, TN · NPI 1679678429
Verified facts
What the public records show
CMS Open Payments records show Darryl John Wilkens, M.D. received $281.49 in general payments during 2025 across 16 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.05 | 50.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 16.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.16 | 14.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.75 | 7.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.68 | 6.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.85 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.49 | 15 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.05 | 10 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
51 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
143 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 823 | 116 |
| Gabapentin | Gabapentin | 587 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 115 |
| Omeprazole | Omeprazole | 456 | 88 |
| Metformin Hcl | Metformin Hcl | 397 | 77 |
| Trazodone Hcl | Trazodone Hcl | 395 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 93 |
| Eliquis | Apixaban | 374 | 48 |
| Lisinopril | Lisinopril | 326 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 322 | 69 |
| Famotidine | Famotidine | 316 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 308 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 306 | 65 |
| Potassium Chloride | Potassium Chloride | 299 | 67 |
| Sertraline Hcl | Sertraline Hcl | 294 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 57 |
| Mirtazapine | Mirtazapine | 223 | 33 |
| Furosemide | Furosemide | 218 | 44 |
| Januvia | Sitagliptin Phosphate | 218 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 207 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 197 | 43 |
| Glimepiride | Glimepiride | 195 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 192 | 30 |
| Montelukast Sodium | Montelukast Sodium | 182 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 159 | 27 |
| Ozempic | Semaglutide | 154 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 154 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 143 | 29 |
| Jardiance | Empagliflozin | 135 | 20 |
| Memantine Hcl | Memantine Hcl | 133 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 129 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 21 |
| Alprazolam | Alprazolam | 120 | 22 |
| Losartan Potassium | Losartan Potassium | 120 | 28 |
| Simvastatin | Simvastatin | 120 | 32 |
| Buspirone Hcl | Buspirone Hcl | 118 | 22 |
| Ibuprofen | Ibuprofen | 118 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 118 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 17 |
| Donepezil Hcl | Donepezil Hcl | 99 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 95 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 15 |
| Farxiga | Dapagliflozin Propanediol | 91 | 18 |
| Naproxen | Naproxen | 90 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 33 |
| Carvedilol | Carvedilol | 84 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 20 |
| Azithromycin | Azithromycin | 80 | 67 |
| Methylprednisolone | Methylprednisolone | 79 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 16 |
| Celecoxib | Celecoxib | 77 | 15 |
| Finasteride | Finasteride | 76 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 19 |
| Benazepril Hcl | Benazepril Hcl | 72 | 13 |
| Metformin Hcl Er | Metformin Hcl | 71 | 11 |
| Meloxicam | Meloxicam | 70 | 16 |
| Allopurinol | Allopurinol | 69 | 16 |
| Estradiol | Estradiol | 69 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 69 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Atenolol | Atenolol | 66 | 13 |
| Ibu | Ibuprofen | 66 | 13 |
| Lorazepam | Lorazepam | 66 | 22 |
| Prednisone | Prednisone | 66 | 22 |
| Pregabalin | Pregabalin | 66 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Sucralfate | Sucralfate | 65 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 50 |
| Bumetanide | Bumetanide | 64 | 17 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 63 | 22 |
| Valsartan | Valsartan | 62 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 61 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 13 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Spironolactone | Spironolactone | 54 | 12 |
| Aripiprazole | Aripiprazole | 52 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 51 | 41 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Linzess | Linaclotide | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Nystatin | Nystatin | 37 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Indomethacin | Indomethacin | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 19 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Cephalexin | Cephalexin | 17 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.49 · 16 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, CAPLYTA, Cologuard Collection Kit, Kerendia, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error